EU reports good progress on developing drugs for children
This article was originally published in Scrip
In its first year of operation, theEuropean Medicines Agency's paediatric committee made good progress towards achieving its aim of facilitating the development of medicines for use in children, according to its annual report.
You may also be interested in...
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.